Primary Immunodeficiency Diseases Market to Rise to US$7.5 bn by 2023

The global primary immunodeficiency diseases market was recorded at US$4.4 bn in 2014. It is expected to exhibit a CAGR of 6.10% within a forecast period from 2015 to 2023. The market could hold a potential value of US$7.6 bn by the end of 2023, according to a research report released by Transparency Market Research. The report, titled “Primary Immunodeficiency Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” is a descriptive compilation of analytical efforts taken to understand this market by industry expert analysts.

Perceive the Report Details for Primary Immunodeficiency Diseases Market: http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

PIDD is a group of rare diseases that are genetic in nature. The commonality among PIDDs is that a section of the immune system is either non-functional or missing. General symptoms of PIDD include extremely low resistance to serious infections or illnesses. This also includes damage to organs as well as life-threatening cases where a body’s immune system starts attacking cells and tissues generated in the body itself. The most common method of treating PIDDs is through the use of human plasma. There are extreme cases of PIDD where a patient will need complete stem cell replacement.

The report explains the global PIDD market using four criteria for categorization: disease, test, treatment, and geography.

On the basis of disease, the global PIDD market is divided into the segments of innate immune disorders, cellular immunodeficiency, and antibody deficiency. Each of these can be further divided into multiple sub-segments consisting of specific diseases and syndromes. The report states that the segment of antibody deficiency diseases topped the global PIDD market in 2014. It is also expected to be the fastest-growing segment of the market in the given forecast period, owing to the high prevalence of antibody deficiency diseases. On average, about 60% to 70% of PIDD cases registered have been from this segment.

The most common, and therefore the most medically significant, antibody deficiency disease is common variable immune deficiency. CVID affects about one in 25,000.

On the basis of test, the global PIDD market is segmented into blood testing and prenatal testing. Of these, the market was led by prenatal tests in 2014 in terms of revenue, owing to the expensive nature of the tests. Prenatal tests are also the first type of test that parents opt for while diagnosing their offspring for PIDD.

In the event that parents find out that the fetus is expected to suffer from PIDDs, they are given the option to discontinue the pregnancy. At the same time, parents who have shown signs of passing on autosomal recessive diseases are also given the option of artificial insemination.

On the basis of treatment, the global PIDD market is divided into immunoglobulin replacement therapy, stem cell and gene therapy, antibiotic therapy, and others. The report expects immunoglobulin replacement therapies to be the fastest-growing segment of the global PIDD market for the given forecast period.

On the basis of geography, the global PIDD market was dominated by North America in 2014, owing to a high rate of diagnosis, the presence of advanced medical care, and the high level of research and development efforts being taken by the top players in this region. In comparison, Asia Pacific and Rest of the World are expected to show a slow rate of growth in the global PIDD market, due to low awareness rates.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

The key players in the global PIDD market are Grifols S.A., Octapharma AG, LFB S.A., Kedrion S.p.A., Bio Products Laboratory Ltd., CSL Behring LLC, Biotest AG, and Baxter International, Inc.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.